Development of a Framework Based on Reflective MCDA to Support Patient–Clinician Shared Decision-Making: The Case of the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the United States

Monika Wagner · Dima Samaha · Hanane Khoury · William M. O’Neil · Louis Lavoie · Liga Bennetts · Danielle Badgley · Sylvie Gabriel · Anthony Berthon · James Dolan · Matthew H. Kulke · Mireille Goetghebeur

Received: September 18, 2017 / Published online: December 21, 2017

© The Author(s) 2017. This article is an open access publication

ABSTRACT

Introduction: Well- or moderately differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are often slow-growing, and some patients with unresectable, asymptomatic, non-functioning tumors may face the choice between watchful waiting (WW), or somatostatin analogues (SSA) to delay progression. We developed a comprehensive multi-criteria decision analysis (MCDA) framework to help patients and physicians clarify their values and preferences, consider each decision criterion, and support communication and shared decision-making.

Methods: The framework was adapted from a generic MCDA framework (EVIDEM) with patient and clinician input. During a workshop, patients and clinicians expressed their individual values and preferences (criteria weights) and, on the basis of two scenarios (treatment vs WW; SSA-1 [lanreotide] vs SSA-2 [octreotide]) with evidence from a literature review, expressed how consideration of each criterion would impact their decision in favor of either option (score), and shared their knowledge and insights verbally and in writing.

Results: The framework included benefit-risk criteria and modulating factors, such as disease severity, quality of evidence, costs, and constraints. Overall and progression-free survival being most important, criteria weights ranged widely, highlighting variations in individual values and the need to share them. Scoring and considering each criterion prompted a rich exchange of perspectives and uncovered individual assumptions and interpretations. At the group level, type of benefit, disease severity, effectiveness, and quality of evidence favored treatment; cost aspects favored WW (scenario 1). For scenario 2, most criteria did not favor either option.

Conclusions: Patients and clinicians consider many aspects in decision-making. The MCDA framework provided a common interpretive
frame to structure this complexity, support individual reflection, and share perspectives.  

**Funding:** Ipsen Pharma.

**Keywords:** Gastroenteropancreatic neuroendocrine tumors; MCDA; Oncology; Shared decision-making

**INTRODUCTION**

Rooted in the ethical imperative for respect of patient autonomy, shared decision-making has become a core aspect of patient-centered care that seeks to empower patients to consider with their physicians the available options, taking into account their personal circumstances and articulating their values, perspectives, and concerns [1–3]. Being promoted as an avenue for improving individual and population health [4], shared decision-making may reduce decisional conflict and improve patient adherence [5]. It is particularly pertinent to contexts of personal uncertainty, when evidence points to multiple, clinically valid therapeutic alternatives [5].

Neuroendocrine tumors (NETs) have been reported to have a rising incidence, likely due to improved diagnosis and classification [6]. Gastroenteropancreatic (GEP) NETs are often slow-growing, with nonspecific symptoms that mimic a variety of disorders, obstructing and delaying diagnosis. Diagnosis typically occurs at an advanced stage, often inadvertently and after metastases have developed [7, 8]. Complete tumor resection is recommended whenever possible [9]. However, for unresectable disease, two randomized, double-blind, placebo-controlled trials, PROMID and CLARINET, demonstrated that the somatostatin analogues (SSAs) octreotide and lanreotide significantly prolong time to progression and progression-free survival (PFS) in patients with well- or moderately differentiated midgut or GEP-NETs, respectively [10, 11]. Both SSAs are administered every 4 weeks, octreotide via intramuscular injection, lanreotide via deep subcutaneous injection with the option of self-administration [12, 13]. On the basis of this evidence, National Comprehensive Cancer Network (NCCN) guidelines recommend, for patients with unresectable, asymptomatic (nonfunctioning) GEP-NET and low tumor burden, either observation with markers and scans (watchful waiting) or initiation of treatment with octreotide or lanreotide [9]. There is no consensus on timing of treatment initiation [9]. The nature of the disease and the different options imply that patients’ preferences and circumstances are central to decision-making in this context, thus suggesting a systematic approach to help identify the relevant factors bearing on the decision and support shared decision-making.

The International Patient Decision Aids Standards (IPDAS) Collaboration recommends that a decision-making tool deliver information about the disease and the available options, including their risks and benefits; clarify and make explicit patient values and preferences; and help share perspectives to support reflection and discussion between patients and physicians [5, 14, 15]. Multi-criteria decision analysis (MCDA) represents a structured and transparent approach to decision-making [16–23]. Sharing the intent of IPDAS, the open-source EVIDEM MCDA framework includes tools to clarify and make explicit individual values, synthesize complex evidence for the decision criteria to facilitate their consideration in real-life scenarios, and help share perspectives through visual outputs and insights [24, 25].

Building on these features, this study's objectives were to (1) explore patients’ and clinicians’ reflection when deciding on management options for unresectable GEP-NET by elucidating which criteria are considered and how they are considered; and (2) develop a comprehensive decision framework that can facilitate elicitation and communication of benefits, risks, preferences, and concerns to help patients and physicians engage in meaningful conversations on the decisions faced. Before application to real-life settings with patient–physician dyads, a small group workshop design, which allowed collection of patients' and physicians' inputs and feedback, was selected to study how such a framework can support reflection and communication (proof-of-concept).
METHODS

Study Overview

The study involved identification and validation of the criteria that are considered by US patients and physicians in their decision-making (including input from a criteria workshop), design of the framework for two decision scenarios, and its application with an extended group of patients and clinicians (decision support workshop) (Fig. 1). Framework design encompassed two approaches: the first focused on the benefits and risks of the management options in the sense of intervention outcomes (core benefit-risk criteria). The second explored the impact of other decision-making factors that may modulate the benefit-risk balance (modulating criteria).

Workshop Design

Patients and clinicians were recruited as experts in decision-making to collect their expert views and insights, stemming from their living with or treating the disease. No clinical data was collected. Both were selected via predefined recruitment criteria (Appendix 1). Clinicians were oncologists specializing in treating patients with locally advanced or metastatic GEP-NET from both academic and community practices. Patients were recruited through patient associations and support groups. All study participants were offered an honorarium as well as reimbursement for their expenses. All participants provided informed consent (patients) or signed agreements (clinicians).

To facilitate open discussion, sessions were held under the Chatham House Rule [26] and were limited to six (three patients, three clinicians) and 11 (five patients, six clinicians) participants for the criteria and the decision support workshops, respectively. Study investigators (i.e., researchers performing the study) guided participants through the workshops.

Criteria Workshop and Design of GEP-NET MCDA Benefit-Risk Trees

At the criteria workshop, patients and clinicians were presented with the 20 generic EVIDEM framework criteria (along with their definitions), organized into seven domains of evaluation [27], plus 10 intervention outcomes subcriteria specific to GEP-NET, which had been identified through targeted review of the scientific literature, including regulatory requirements for oncology trials [28, 29]. Participants were asked to validate each (sub)criterion and suggest others for inclusion. For framework design, to allow the expression of a broad range of perspectives, a (sub)criterion was included if at least one participant deemed it to be relevant. (See Appendix 2 for (sub)criteria.) The core and modulating (sub)criteria were organized by domain into a core benefit-risk and a modulated benefit-risk tree, respectively.

Decision Scenarios and Evidence on GEP-NET and Management Options

Two decision scenarios were defined on the basis of current practice guidelines [9]: the first explored the primary decision whether to initiate treatment with an SSA (using lanreotide as reference case) or to pursue watchful waiting; and the second explored the decision between two SSAs treatments: treatment 1 (lanreotide) versus treatment 2 (octreotide). To provide necessary and sufficient evidence to assign a score for each criterion, MCDA evidence matrices for each scenario were created following EVIDEM methodology [27], which entails a standardized approach for the identification, analysis, synthesis, and reporting of evidence.

Evidence was obtained from public sources, including major biomedical literature databases (PubMed/Medline), Cochrane systematic reviews, clinical trial registries, conference websites (ASCO, NANETS), and bibliographies of full-text articles. Additional sources were patient and professional association websites. Recent peer-reviewed, comprehensive studies were preferentially selected; for clinical data,
only key phase 3 or 4 randomized controlled trials (RCTs) and prospective studies were eligible for inclusion. (See Supplementary Appendix 4 for more details on the targeted systematic literature review methodology.) The evidence matrix included 33 references.

Fig. 1 Study overview. Colloquial evidence: “anything that establishes a fact or gives reason for believing something” [55]
Decision Support Workshop

At the decision support workshop, participants were first introduced to the approach and the definitions of the decision criteria and then asked to express their individual value systems and preferences by weighing the relative importance of the criteria (independently of the scenarios). Next, participants explored scenario 1: on the basis of the evidence matrix (see excerpt in Appendix 5), the available evidence for a criterion was presented by study investigators, then the group exchanged their comments and insights, which was followed by each participant providing his/her individual score, comments, and insights in writing. Scores were provided using a constructed, cardinal scale, designed to capture individual interpretations, and expressed how consideration of each criterion would impact the decision, ranging from \(-5\) (much in favor of option 1) to \(+5\) (much in favor of option 2). For qualitatively considered criteria, participants indicated how their consideration impacted their decision (positive, no, or negative impact). Participants were also asked to provide for each criterion any additional information they wanted to see. This was repeated for each criterion and then for scenario 2. Feedback on the process was collected through structured discussion and in written form.

Data Analysis

As reported previously [25], the relative benefit-risk balance (RBRB) is defined as the sum of the benefit-risk contributions (BRCx) of all \(n\) subcriteria of the benefit-risk tree, where BRCx is the product of the normalized weight \((W_x, \sum W_x = 1)\) and standardized score \((S_x = \text{score}/5)\) for the subcriterion \(x\) (linear additive model):

\[
\text{RBRB} = \sum_{x=1}^{n} \text{BRC}_x = \sum_{x=1}^{n} (W_x \times S_x)
\]

For example, if the criterion impact on autonomy received a normalized weight of 0.1 and a score of +2, its contribution to the RBRB was \(0.1 \times 2/5 = +0.04\). RBRBs can range from \(-1\) to \(1\). Positive RBRBs indicate that the sum of the criteria contributions favors option 1 and negative RBRBs favor option 2. A corresponding linear additive model including all core and modulating (sub)criteria was used to derive the modulated RBRB (mRBRB).

As the approach was designed to be applied at the individual level for patient–physician interactions, weights, scores and RBRBs were computed at the level of individual participants. For the purpose of illustration and reporting, mean values were calculated and are presented here at the group level. Variability across participants was quantified using standard deviations (SD). Written and verbal comments were organized and summarized by criteria. Visual representations of the outputs were designed.

Face Validity and Exploration of Uncertainty

To assess face validity, participants received a visual and tabular representation of their own assessment (including weights, RBRBs, mRBRBs, and qualitative impacts) and were asked whether this reflected their reasoning during the exercise. To explore impact on weights distribution, two weighting methods were used: hierarchical point allocation (HPA), which involved distributing weighting points across the domains, criteria, and subcriteria of the benefit-risk trees, was used for the primary analysis [24]. For an alternative analysis, the direct rating scale (DRS) method was used [30], which involves rating the relative importance of each (sub)criterion on a scale from 1 to 5. Using the sum of these rates as denominator, relative weights for each (sub)criterion were calculated and used to compute the RBRBs.

RESULTS

Criteria Workshop: What Matters?—Criteria Set Adaptation and Validation

Of the 30 (sub)criteria presented to the criteria workshop participants, 26 were considered relevant by more than 90% of the participants.
Participants unanimously agreed on the relevance of the core benefit-risk subcriteria, progression-free survival, worsening of symptoms, health-related quality of life (HRQoL), impact on autonomy, impact on dignity, serious adverse events, and fatal adverse events to their evaluation of GEP-NET management options. All other outcomes presented were deemed relevant by at least one-third of the participants. Tumor regression rate was identified as an additional relevant outcome and was incorporated in the core benefit-risk tree (Fig. 2a).

Modulating factors deemed relevant by all were type of therapeutic benefit, disease severity, unmet needs, costs/constraints to patients, and quality of evidence. Population priorities and access were unanimously considered not relevant and therefore omitted from the framework. On the basis of participant input, subcriteria were created to segregate costs and constraints incurred by patients from those incurred by the healthcare system, and system capacity and appropriate use was incorporated into the modulated tree for quantitative consideration (Fig. 2b).

Fig. 2 MCDA core benefit-risk tree (a) and modulated benefit-risk tree (b). *Qualitatively assessed criteria
Decision Support Workshop Step 1: What are the Trade-Offs?—Clarifying Values and Preferences

Weighting the criteria of the core benefit-risk tree, decision support workshop participants assigned the greatest relative weight to overall survival (mean normalized weight 0.16, scale 0 to 1), followed by progression-free survival (0.15), fatal adverse events (0.14), and disease symptoms (0.11) (Fig. 3a). Level of chromogranin A (0.01), and convenience and ease of use (0.04) received the least weight. Progression-free survival (SD ±0.15) and overall survival (±0.12) showed the largest variations in weights.

In the modulated tree (Fig. 3b), comparative effectiveness received the greatest mean weight (0.18), followed by disease severity (0.12), comparative safety/tolerability (0.10), and type of therapeutic benefit (0.10). The least weight was assigned to size of affected population (0.02) and non-medical costs and constraints (0.03). Participants’ weights varied most for comparative effectiveness (±0.12), disease severity, and quality of evidence (±0.10). Among the economic consequences and constraints subcriteria, cost of intervention to patient received the greatest normalized weight (0.04), followed by non-medical costs and constraints (0.03) and other medical costs and constraints to patients (0.03) (data not shown).

Decision Support Workshop Step 2: How Does Consideration of Each Criterion Favor Either Option?—Criteria Scores and Insights

Scoring, on the basis of the available evidence and personal insights, how consideration of each criterion favors either option prompted a rich exchange of knowledge and rationales among participants. Details—including a condensed summary of the evidence available to the participants as well as the scores and comments they provided—are presented for scenario 1 (watchful waiting vs treatment [lanreotide]) in Table 1 (core benefit-risk criteria) and 2 (modulating criteria). A high-level summary is reported for scenario 2 further on.

For comparative effectiveness, data on PFS was seen as clearly favoring treatment over watchful waiting, with a mean score of 4.0 (±1.2, scale –5 to 5) (Table 2). While it was noted that the PFS appeared to encourage a low threshold for starting SSA therapy, participants raised questions around the relevance of the RCT data to clinical practice regarding patient population and the criteria to define progression. Overall survival (OS), the criterion that had received the highest weight, was scored slightly in favor of treatment (mean 0.3 ± 2.2). Clinicians noted that the trial was not designed to measure OS and that this outcome would be difficult to quantify. No data was available on effect on tumor-related disease symptoms in the target population; nevertheless, most participants scored this criterion as favoring SSA therapy (mean 2.9 ± 2.1), in part because of its well-known symptom relief effects. The effect on level of chromogranin A was also considered to be in favor of treatment (1.2 ± 1.9), but clinicians commented that its usefulness in decision-making was limited (Table 1).

For comparative patient-perceived health/PROs, consideration of HRQoL marginally favored treatment (mean 0.5 ± 1.8). Clinical trial data showed no significant difference in HRQoL outcomes. Some participants commented that treatment-induced PFS extension would be expected to have a positive emotional impact, whereas receiving no treatment could take an emotional toll. Comments on impact on autonomy and convenience/ease of administration revolved around the option of lanreotide self-injection, its relation to insurance coverage, and its impact on office visits. Although scores varied widely, generally autonomy in drug administration was viewed as favoring treatment (1.0 ± 2.6), whereas overall convenience aspects favored watchful waiting (–1.3 ± 2.0), which, as commented by one participant, was particularly relevant for frail patients (Table 1).

Among comparative safety/tolerability subcriteria, non-serious AEs and non-fatal serious AEs moderately favored watchful waiting (mean
scores $-1.3 \pm 1.5$ and $-0.5 \pm 0.9$), whereas fatal AEs did not favor either option ($0.0 \pm 0.0$), congruent with the absence of fatal AEs in the pivotal trial. Participants stressed that potential AEs must be considered, especially as treatment is initiated in asymptomatic patients. They also noted that more information on the management of side effects, their impacts, and whether or not they are reversible would have been helpful.

Among modulating criteria (Table 2), the type of therapeutic benefit lanreotide provides
was considered to be in favor of treatment (3.8 ± 1.7). One participant commented that “Keeping the disease stable is very significant.” Consideration of disease severity and unmet needs favored treatment overall (2.5 ± 2.7 and 2.1 ± 1.6), but views differed widely, particularly with respect to disease severity where scores ranged from −2 to 5. On the watchful

Table 1 Core benefit-risk criteria: condensed evidence and participant scores and comments exploring scenario 1: treatment (lanreotide as a reference case) versus watchful waiting

| CONDENSED EVIDENCE SYNTHESIS BY CRITERION | MEAN SCORE (SD) | COMMENTS |
|------------------------------------------|----------------|----------|
| COMPARATIVE EFFECTIVENESS                |                |          |
| Progression-free survival                |                |          |
| CLARINET: [11] lanreotide: median not reached; Placebo: median 18 months, range 12.1–24.2; HR: 0.47 (95% CI 0.30–0.73); P < 0.001 |
| | 4.0 (1.2) | • PFS benefit appears to encourage low threshold for starting lanreotide in newly diagnosed patients. |
| |                | • “While PFS is an extremely useful endpoint, its clinical importance is less established in NETs. A progression per RECIST may not be clinically relevant.” |
| |                | • “The population in CLARINET was the ‘slowest of the slow’ NETs…” |
| |                | • “…50% of placebo arm did not progress for 18 months … would have preferred study patients to already have progressive disease.” |
| |                | • Additional information desired: comparisons with other treatment options |
| Disease symptoms                          |                |          |
| No data on tumor-related symptoms for either option |
| | 2.9 (1.1) | • “Although CLARINET did not assess symptom control, we know that lanreotide is effective in controlling symptoms of carcinoid syndrome.” |
| |                | • “No data hence not a consideration.” |
| |                | • Lack of data on diseases symptoms may suggest not helpful. |
| Tumor regression rate                      |                |          |
| No data for either option                  |                |          |
| | 0.4 (2.1) | • Tumour stability may be as good as regression if no symptoms. |
| |                | • Regression (secondary to SSA) is not to be expected. |
| Overall survival                           |                |          |
| CLARINET: [11] No statistically significant difference between lanreotide and placebo |
| | 0.1 (2.2) | • Data on OS is not available to be discussed with patient. |
| |                | • Trial was not designed to measure survival. |
| |                | • Other interventions given over time may also impact survival. |
| |                | • “OS will be very difficult to quantify given that most, if not all, patients will eventually receive SSAs.” |
| Level of chromogranin A                    |                |          |
| CLARINET: [11] % of pts with >50% reduction: Lanreotide: 42%; placebo: 5%, P < 0.001 |
| | 1.2 (1.6) | • Use of chromogranin A is controversial and its utility is limited. |
| |                | • There is not necessarily a correlation between chromogranin A and symptoms. |
| |                | • “Only asymptomatic patients included in trial.” |
| |                | • “If treatment lengthens PFS it would impact on emotional well-being, but my score is 0 based on these data.” |
| |                | • “Would have favored the drug more if QoL improved.” |
| |                | • “Insurance often does not cover self-injection and co-pays vary so most patients must use office-based treatment, in theory self-injection is desirable.” |
| |                | • “Would love to self-inject but most important is that co-insurance cost is too high.” |
| |                | • “Autonomy in drug administration would improve QoL.” |
| COMPARATIVE PATIENT-PERCEIVED HEALTH / PROS |                |          |
| HRQoL                                     |                |          |
| CLARINET: [11] No significant differences between lanreotide and placebo in EORTC QLQ-C30 and EORTC QLQ-GI.NET21 scores |
| | 0.5 (1.8) | • “Only asymptomatic patients included in trial.” |
| |                | • “Doing nothing has an emotional toll on patients.” |
| |                | • “If treatment lengthens PFS it would impact on emotional well-being, but my score is 0 based on these data.” |
| |                | • “Would have favored the drug more if QoL improved.” |
| Impact on autonomy                         |                |          |
| Lanreotide phase IV trial: [43] patients preferring self-injection experienced more independence (reduced visits to clinic). “Partner can handle injections when travelling.” Watchful waiting: No data |
| | 1.0 (2.4) | • “Insurance often does not cover self-injection and co-pays vary so most patients must use office-based treatment, in theory self-injection is desirable.” |
| |                | • “Would love to self-inject but most important is that co-insurance cost is too high.” |
| |                | • “Autonomy in drug administration would improve QoL.” |
| Impact on dignity                          |                |          |
| No data for either option                  |                |          |
| | 0.4 (1.3) | • Increased flatulence with lanreotide affects QoL. |
| |                | • As there is no data on how treatment affects appearance, it is not important in this case. |
| |                | • “Insurance often does not cover self-injection and co-pays vary so most patients must use office-based treatment, in theory self-injection is desirable.” |
| |                | • “Would love to self-inject but most important is that co-insurance cost is too high.” |
| |                | • “Autonomy in drug administration would improve QoL.” |
| Convenience / ease of use / mode of setting administration                      |                |          |
| Lanreotide: prefilled syringe allows self-administration, [12, 44] 88% of pts preferred self-injection because time saving, practical, avoid hospital visits. [43] Watchful waiting: blood tests and scans every 3-12 months [9] |
| | -0.3 (2.8) | • Aside from flexibility for vacations, there is no difference in number of doctor visits. |
| |                | • This criterion might be scored differently if self-injection is covered or not. |
| |                | • “Insurance often does not cover self-injection and co-pays vary so most patients must use office-based treatment, in theory self-injection is desirable.” |
| |                | • “Would love to self-inject but most important is that co-insurance cost is too high.” |
| |                | • “Autonomy in drug administration would improve QoL.” |
| |                | • “If treatment is not necessary, convenience is not important.” |
| |                | • “Would not make ease of administration a reason to start therapy.” |
waiting side, it was commented that “In slow-growing asymptomatic tumors the benefit of any treatment is unclear”, whereas on the treatment side, a patient stated that “Doing something is better than doing nothing.” It was also noted that the favored option would depend on the presence of co-morbidities.

With respect to economic consequences and constraints, considerations around the cost of treatment to patients, in terms of co-payments, deductibles, and possible increases in monthly contributions, favored watchful waiting (mean score – 2.8 ± 1.8). Other medical and non-medical costs and constraints for patients also favored watchful waiting (–1.2 ± 1.3 and –1.0 ± 1.6, respectively). It was noted that there may be additional costs and medical appointments if patients experience side effects. Patients expressed major concerns about time away from work and family, travel costs, and fear of losing employment as a result of insurance charges.

Both quality of evidence and expert consensus/clinical practice guidelines (CPGs) were viewed in favor of treatment (2.9 ± 1.8 and 2.2 ± 2.8). Participants commented that CLARINET was well conducted but it was only one trial. (Note the PROMID trial was presented for scenario 2 only.) With respect to CPGs, clinicians noted that the guidelines provide general guidance but treatment decisions are driven by individual patient characteristics.

Across all (sub)criteria, the greatest variations in scores (SD ≥ 2.0) were for overall survival, disease symptoms, tumor regression rate, impact on autonomy, convenience/ease_MODE_of administration, disease severity, expert consensus/CPGs, and system capacity/appropriate use (Tables 1, 2).

Qualitative criteria were considered by the majority of participants but had no impact on their decision-making. Several participants indicated that mandate and scope of the healthcare system was in favor of treatment, while opportunity costs and affordability were in favor of watchful waiting (data not shown).

Decision Support Workshop Step 3: What is the Overall Balance Between the Criteria?

Combining weights and scores, at the group level, an RBRB of 0.18 (±0.20) favored treatment (with lanreotide as reference case) over watchful waiting (Fig. 4). Progression-free survival (0.12 ± 0.13) and disease symptoms (0.06 ± 0.06) contributed most to the RBRB in favor of treatment. Non-fatal non-serious adverse events (–0.02 ± 0.03), non-fatal serious adverse events (–0.01 ± 0.02), and convenience (–0.01 ± 0.01) contributed most
Table 2 Modulating benefit-risk criteria: condensed evidence and participant scores and comments exploring scenario 1: treatment (lanreotide as a reference case) versus watchful waiting

| CONDENSED EVIDENCE SYNTHESIS BY CRITERION | MEAN SCORE (SD) | COMMENTS |
|--------------------------------------------|----------------|----------|
| **TYPE OF BENEFIT OF INTERVENTION**         |                |          |
| Type of therapeutic benefit                |                |          |
| Lanreotide: delay in disease progression    | 1.8 (1.7)      | ▪ Keeping the disease stable is very significant. |
| Watchful waiting: NA                       |                | ▪ PFS is a good endpoint to recommend treatment even if OS data not available. |
| Type of preventive benefit                 | 0.3 (1.5)      | ...      |
| No data                                    |                |          |
| **NEED FOR INTERVENTION**                  |                |          |
| Disease severity                           | 2.1 (2.7)      | ▪ Understand that studies are short but GEP-NETs are slow growing |
| Slow growing tumors, no defining symptoms, |                | ▪ "In slow-growing asymptomatic tumors the benefit of any treatment is unclear—could wait to begin treatment at progression." |
| 60% metastasized at diagnosis;[46]         |                | ▪ Depending on overall individual life expectancy, would recommend lanreotide for patients with expected 5 to 10 years survival but watchful waiting for patients with limited survival due to comorbidities. |
| Survival: 5-year: 87.4% GI GEP-NETs;[47]    |                | ▪ Much more in favor of watchful waiting |
| 64% well differentiated nonfunctioning     |                | ▪ "Doing something is better than doing nothing." |
| GEP-NETs;[48] median: 3.9–7.9 years;[49]   |                | ▪ Multiple other options are available. |
| (Qol. impact: physical function and general |                | ▪ This does not change decision on whether or not to try active treatment. |
| health);[49] 5-year OS: 87.4% GI          |                |          |
| GEP-NETs;[47] 64% well differentiated      |                |          |
| nonfunctioning GEP-NETs;[48] median: 3.9– |                |          |
| 7.9 years;[49] (QoL impact: physical       |                |          |
| function and general health (SF-36, PROMIS-29);[50] Utilities: |                |          |
| 0.7 stable disease, 0.61 progressive       |                |          |
| disease, 0.56–0.78 with treatment AEs[51]  |                |          |
| Unmet needs                                | 2.1 (1.4)      | ▪ Incidence and prevalence do not dictate treatment course and are not relevant. |
| No recommended treatment options other than |                |          |
| lanreotide or octreotide and watchful      |                |          |
| waiting[7]                                 |                |          |
| Size of population                         | 0.4 (1.1)      |          |
| Prevalence: 21.6/100,000 for GI GEP-NET,  |                |          |
| 13/100,000 for pancreas and digestive      |                |          |
| organs[48]; Incidence: 5.00/100,000[6]     |                |          |
| **ECONOMIC CONSEQUENCES AND CONSTRAINTS OF INTERVENTION** |        |          |
| Cost of intervention to patient            |                |          |
| Lanreotide: $14,288, if 20% co-            | -2.8 (1.6)     | ▪ Cost is a major factor for patients at any time. |
| payment[54]                                 |                | ▪ Multiple things to be considered: co-payments, annual deductibles, etc. |
| Watchful waiting: no data                  |                | ▪ "Some impact of cost but given known PFS benefit, effect is not large." |
| Cost is a major factor for patients at any |                | ▪ Regardless of insurance coverage, there will always be certain financial toxicities from treatment and its side effects. |
| time.                                      |                | ▪ Discussion around cost may make patients more comfortable with choosing watchful waiting. |
| Cost of intervention to the healthcare     | -3.2 (1.8)     | ▪ Economic impact on insurer not a direct concern for patients |
| system                                      |                | ▪ There is a significant difference between acquisition cost and what is billed to a patient’s insurance. |
| Lanreotide: $73,442 per year, derived from |                | ▪ Cost to the insurance may increase patients’ monthly contributions. |
| published data[52,53]                      |                |          |
| Watchful waiting: no data                  |                |          |
| Other medical costs & constraints to the   | -1.2 (1.1)     | \* Less frequent healthcare visits with watchful waiting than with lanreotide |
| patient                                     |                | \* "Time missed from work and family, travel to hospital, travel costs, additional medical appointments for related concerns." |
| No data for either option                  |                | \* There could be substantial additional costs if patient experiences side effects. |
| Other medical costs & constraints to the   | -0.9 (1.1)     | \* Transportation costs & time are an inconvenience but medication benefit is much more important." |
| healthcare system                          |                |          |
| Lanreotide: stable disease[52,54] procedures and tests: $6,110, physician visits: $4,121, hospitalizations: $18,278 |                |          |
| Watchful waiting: no data                  |                |          |
| Other medical costs and constraints to the | -1.0 (1.4)     | \* Very important consideration |
| healthcare system                          |                | \* Fear of losing employment, impact on caregiving (parenting) time |
| Lanreotide: stable disease[52,54] procedures and tests: $6,110, physician visits: $4,121, hospitalizations: $18,278 |                | \* Few extra visits needed |
| Watchful waiting: no data                  |                |          |
| Non-medical costs and constraints          | -1.0 (1.4)     |          |
| No data for either option                  |                |          |
towards watchful waiting. The largest variations among participants were noted for progression-free survival and impact on autonomy (±0.13 and ±0.07).

Taking into account modulating criteria, at the group level, an mRBRB of 0.29 favored treatment over watchful waiting, with large individual variations (±0.28). Beside comparative effectiveness (0.07 ± 0.08), type of therapeutic benefit, disease severity, and quality of evidence contributed most towards treatment (0.08 ± 0.06, 0.07 ± 0.12, and 0.06 ± 0.10), whereas economic considerations, including cost of intervention and other medical costs and constraints, favored watchful waiting (−0.03 ± 0.02 and −0.01 ± 0.02).

For scenario 2 (treatment 1 [lanreotide] vs treatment 2 [octreotide]), the majority of criteria did not favor one option over another, with mean RBRB (0.00 ± 0.04) and mRBRB (0.01 ± 0.04) close to 0 at the group level (data not shown). Participants commented that although the pivotal trials (PROMID and CLARINET) were difficult to compare because of different patient populations, effectiveness, impact on HRQoL, and safety and tolerability appeared to be similar. With respect to the RBRB, convenience/ease of use (0.02 ± 0.01) and impact on autonomy (mean 0.01 ± 0.01) contributed to favoring lanreotide, as participants commented, owing to the possibility to self-inject and potentially less painful injection, while tumor regression rate (−0.01 ± 0.03) contributed towards octreotide (no data on lanreotide). With respect to the mRBRB, system capacity (0.02 ± 0.02) contributed in favor of lanreotide, while cost of intervention favored octreotide (−0.02 ± 0.02) (participants used cost comparison data and their own knowledge/experience), although with large variations across participants.

Face Validity and Exploration of Uncertainty

All of the seven participants who participated in the face validity exercise noted that the visual representations of their quantitative outputs (i.e., weights, RBRBs, and mRBRBs) reflected...
their thinking process. One participant commented specifically that the visual representation clarified how the combination of relative weights and the consideration of available evidence had impacted their thought process.

Replacing HPA-derived with DRS-derived weights shifted the mean RBRB for scenario 1 from 0.18 (± 0.20) to 0.14 (± 0.19) and the mRBRB from 0.29 (± 0.28) to 0.19 (± 0.20). For scenario 2, DRS-derived weights shifted the RBRB and the mRBRB slightly more in favor of lanreotide, from 0.00 (± 0.04) to 0.04 (± 0.04) and from 0.01 (± 0.04) to 0.02 (± 0.04), respectively.

**Participants’ Feedback on Experience and Process**

At the end of the exercise, participants noted that the criteria discussed reflected questions with which they struggle and highlighted the importance of conducting a shared reflection on these criteria. They also emphasized the importance of considering the available evidence, while noting its limitations in real-world applications. One participant would have wanted more time to read and process the information. In general, participants found the process innovative and helpful since it allowed them to structure their thinking and make it more explicit, which allowed it to be shared with others. The interactive component of the exercise was found to foster an environment where patients and clinicians had the opportunity to discuss sensitive elements. This was appreciated by all participants.

**DISCUSSION**

Investigating a complex clinical decision problem on the basis of a range of criteria and the available evidence allowed an in-depth exploration of what matters and how it matters to patients and clinicians. This exploration revealed that a variety of criteria are relevant to the reality of decision-making, including potential clinical and patient-reported outcomes, but also other factors, such as disease severity, quality of evidence, type of benefit, and personal costs and constraints. This suggests that true understanding of the decision requires embracing its complexity, which also has to be reflected in a framework that is intended to support the decision-making process. This is echoed in other work reporting that, beyond clinical factors, family situation, impact on family and work as well as disease stage are important for cancer patients’ decision-making [31].

Assigning criteria weights prompts stakeholders to reflect on their values and preferences (i.e., what matters most to them). In the GEP-NET management context, on the group level, OS and PFS were the most important outcomes, closely followed by fatal AEs. PFS is recommended as primary endpoint for NET trials, while OS is deemed not a practical endpoint because of important trial design constraints [32]. Thus, although observational data suggests a correlation between PFS and OS [33], a reliable estimate of the OS benefit associated with SSA therapy is likely to remain unavailable.

Weights varied widely, highlighting differences in values and preferences and the importance of communication. Although the study was not designed to compare patient and clinician perspectives, exploratory analysis suggests that, while clinicians tended to assign greater importance to efficacy outcomes, patients put greater emphasis on fatal and serious AEs (mean normalized weights vs clinicians: fAEs: 0.18 vs 0.11, sAEs: 0.11 vs 0.06). Recent studies confirm that risk aversion differs from one group to another [34–36] and also varies depending on patients’ health status, as lower disease severity correlates with less willingness to accept risk [31, 35]. Compared to clinicians, patients also tended to assign greater weight to the criteria impact on autonomy and impact on dignity at the expense of impact on HRQoL, which may suggest that these terms more directly expressed what matters to patients than the HRQoL concept, as was discussed previously [37, 38].
assumptions as related to the decision [41]. The scoring exercise, including the comments it elicited, helped uncover assumptions and differences in interpretation. Particularly when data was absent or inconclusive, large variations in scores were observed, reflecting uncertainty and diversity of views. For example, for overall survival, one-quarter of participants provided positive scores, thus expressing their expectation that treatment may extend survival even though the clinical study design was not able to show an OS benefit. Scores for disease severity showed particularly large variation (SD 2.7), indicating that the same information on the natural course of the disease can be interpreted in favor of either opinion, as was also confirmed by the comments provided. It is also possible that participants’ own experience with the disease and its symptoms played into how they considered this criterion. Sharing scores with others can bring interpretations to light, and thereby help patients and clinicians understand each other’s reasoning in order to create a “shared mind”, which, as Epstein and Street noted, is central to achieving truly shared decision-making [41].

Combining weights and scores across criteria (RBRB) indicates that, at a group level, patients and clinicians preferred treatment rather than watchful waiting (scenario 1). This appears to be in line with the natural progression of the disease and comments from physicians that eventually all patients would receive SSA therapy. Group discussion also highlighted the emotional impact of “doing something” following a GEP-NET diagnosis. Beyond core benefit-risk criteria, disease severity, type of benefit, and quality of evidence played impactful modulating roles in patients’ and clinicians’ considerations. With respect to scenario 2, on a group level, the RBRB and mRBRB did not appear to favor one treatment option over the other, although some of the decision criteria were deemed in favor of one SSA or the other.

Exploratory analysis suggested that safety/tolerability contributed in favor of watchful waiting among clinicians but not patients. This likely reflects the relatively safe profile of SSAs. In their comments, patients highlighted their willingness to accept non-serious AEs if treatment slows disease progression. Other studies also observed that drug effects may be valued differently by patients and physicians [42].

While participants deemed the visual representation of their assessment helpful and affirmed its face validity, the potential value of a decision framework lies not primarily in quantitative outputs but in its ability to stimulate fruitful conversations about values, preferences, the evidence and its meaning [3]. To that end, weighting provided a means for sharing values and preferences, while scoring scales were designed to help decision-makers express their thinking in a semi-quantitative way, which, combined with insights, can be easily shared with others. The comprehensiveness of the framework helped conversations go beyond risks and benefits to include autonomy, convenience, feasibility, personal costs and constraints, and affordability. Feedback from participants highlighted the usefulness of the exercise to clarify the complexity of decision-making and support communication.

This study had several limitations. First, as a result of lack of data, for some of the criteria (e.g., non-medical costs and constraints) participants had to rely solely on their own insights and experiences to inform their reflection. In practice, accurate cost information is often not available at the time of decision-making, although, as was shown, study participants saw cost considerations as very relevant to decision-making. Further, in real-life applications, the benefit of a decision framework lies at the individual level and for patient–physician interactions. In this study, results are presented on a group level to illustrate the approach and identify aspects relevant to the management of GEP-NET. However, in view of the relatively small number of participants and the large variability in how individuals consider evidence and make trade-offs, these group values should be interpreted with caution and are not broadly generalizable. Still, the small workshop format was designed to create an atmosphere where patients and physicians could freely exchange perspectives and thus allowed an in-depth exploration of thought processes, to the benefit of the larger GEP-NET community.
CONCLUSION

The multi-criteria framework offered patients and clinicians a common interpretive frame to structure the complexity of decision-making, support individual reflection, and help share what matters to them and how it matters when exploring treatment decisions for unresectable, asymptomatic, non-functioning, well- or moderately differentiated GEP-NETs. This work can be leveraged to provide a decision-making tool for the clinical setting (e.g., a Web-based application)—which features relevant criteria, scientific evidence, and tools to elicit individual values, preferences, judgments, and insights—to support patients and clinicians in jointly arriving at evidence-informed decisions.

ACKNOWLEDGEMENTS

The authors would like to acknowledge the participating physicians and patients. We would like to thank the Carcinoid Cancer Foundation for their support in recruiting patients.

Funding. This study was sponsored by Ipsen Pharma. The sponsor also provided funding for the journal’s article processing charges and the Open Access fee. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

Disclosures. Danielle Badgley is an employee of Analytica Laser, which has received consulting fees from Ipsen Pharma for the conduct of the study and writing of the manuscript. Dima Samaha is an employee of Analytica Laser, which has received consulting fees from Ipsen Pharma for the conduct of the study and writing of the manuscript. Louis Lavoie is an employee of Analytica Laser, which has received consulting fees from Ipsen Pharma for the conduct of the study and writing of the manuscript. Mireille Goetghebeur at the time of the study was an employee of Analytica Laser, which has received consulting fees from Ipsen Pharma for the conduct of the study and writing of the manuscript. Mireille Goetghebeur’s current affiliation is the School of Public Health, University of Montreal, Montreal, Canada. Monika Wagner is an employee of Analytica Laser, which has received consulting fees from Ipsen Pharma for the conduct of the study and writing of the manuscript. William O’Neil is an employee of Analytica Laser, which has received consulting fees from Ipsen Pharma for the conduct of the study and writing of the manuscript. Matthew Kulke has received consulting fees from Lexicon, Novartis, and Ipsen. Anthony Berthon is an employee of Ipsen Pharma. Sylvie Gabriel is an employee of Ipsen Pharma. James Dolan has nothing to disclose.

Compliance with Ethics Guidelines. All study participants, patients and clinicians were recruited as experts to collect their expert views and insights. No clinical data was collected. All participants provided informed consent (patients) or signed agreements (clinicians).

Data Availability. The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit
REFERENCES

1. Braddock CH III. Supporting shared decision making when clinical evidence is low. Med Care Res Rev. 2013;70(1 Suppl):129S–40S.

2. Kunneman M, Montori VM, Castaneda-Guarderas A, Hess EP. What is shared decision making? (and what it is not). Acad Emerg Med. 2016;23(12):1320–4.

3. Hargraves I, LeBlanc A, Shah ND, Montori VM. Shared decision making: the need for patient-clinician conversation, not just information. Health Aff (Millwood). 2016;35(4):627–9.

4. Frosch DL, Moulton BW, Wexler RM, Holmes-Rovner M, Volk RJ, Levin CA. Shared decision making in the United States: policy and implementation activity on multiple fronts. Z Evid Fortbild Qual Gesundhwes. 2011;105(4):305–12.

5. Legare F, Witteman HO. Shared decision making: examining key elements and barriers to adoption into routine clinical practice. Health Aff (Millwood). 2013;32(2):276–84.

6. Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.

7. Vinik AI, Chaya C. Clinical presentation and diagnosis of neuroendocrine tumors. Hematol Oncol Clin N Am. 2016;30(1):21–48.

8. International Neuroendocrine Cancer Alliance. Global survey. 2016. http://incalliance.org/tag/global-survey/. Accessed 21 Jul 2016.

9. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Neuroendocrine tumors. Version 1.2015. 2014. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 12 Nov 2015.

10. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–63.

11. Caplin ME, Pavl M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–33.

12. Ipsen Pharma Biotech. Prescribing information. Somatuline depot. 2014.

13. Novartis Pharmaceuticals Corporation. Prescribing information. Sandostatin LAR Depot. 2014.

14. O’Connor A, Elwyn G, Barratt A, Barry M, Coulter A. IPDAS 2005: Criteria for judging the quality of patient decision aids. 2005. http://ipdas.ohri.ca/IPDAS_checklist.pdf. Accessed 13 Dec 2016.

15. Elwyn G, Frosch D, Thomson R, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27(10):1361–7.

16. Baltussen R, Niessen L. Priority setting of health interventions: the need for multi-criteria decision analysis. Cost Eff Resour Alloc. 2006;4:14.

17. Tunis SR. Reflections on science, judgment, and value in evidence-based decision making: a conversation with David Eddy. Health Aff (Millwood). 2007;26(4):w500–15.

18. Goetghebeur MM, Wagner M, Khoury H, Rindress D, Greigore JP, Deal C. Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients. Cost Eff Resour Alloc. 2010;8(1):4.

19. Dolan JG. Multi-criteria clinical decision support: a primer on the use of multiple-criteria decision-making methods to promote evidence-based, patient-centered healthcare. Patient. 2010;3(4):229–48.

20. Thokala P, Devlin N, Marsh K, et al. Multiple criteria decision analysis for health care decision making - an introduction: report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016;19(1):1–13.

21. Dolan JG, Boohaker E, Allison J, Imperiale TF. Patients’ preferences and priorities regarding colorectal cancer screening. Med Decis Making. 2013;33(1):59–70.

22. Dolan JG, Boohaker E, Allison J, Imperiale TF. Can streamlined multicriteria decision analysis be used to implement shared decision making for colorectal cancer screening? Med Decis Making. 2014;34(6):746–55.

23. Dolan JG. Patient priorities in colorectal cancer screening decisions. Health Expect. 2005;8(4):334–44.
24. Tony M, Wagner M, Khoury H, et al. Bridging health technology assessment (HTA) with multi-criteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada. BMC Health Serv Res. 2011;11:329.

25. Goetghebeur MM, Wagner M, Nikodem M, Zyla A, Micaleff A, Amzal B. Pragmatic multicriteria decision analysis (MCDA) combined with advanced pharmacoepidemiology for benefit-risk assessments of medicines adapted to the real-life constraints of regulators: development and case study. Ther Innov Regul Sci. 2016;50(5):620–31.

26. Royal Institute of International Affairs. Chatham House Rule. 2002. https://www.chathamhouse.org/about/chatham-house-rule. Accessed 15 Sep 2015.

27. EVIDEM Collaboration. Evidence and Value: Impact on DEcisionMaking. 2015. https://www.evidem.org/. Accessed 17 Sep 2015.

28. European Medicines Agency. Guideline on the evaluation of anticancer medicinal products in man. 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/12/WC500119966.pdf. Accessed 23 Aug 2012.

29. US Food and Drug Administration. Guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics. 2007. http://www.fda.gov/downloads/Drugs/…/Guidances/ucm071590.pdf. Accessed 4 Aug 2015.

30. van Til J, Groothuis-Oudshoorn C, Lieferink M, Dolan J, Goetghebeur M. Does technique matter; a pilot study exploring weighting techniques for a multi-criteria decision support framework. Cost Eff Resour Alloc. 2014;12:22.

31. Zafar SY, Alexander SC, Weinfurt KP, Schulman KA, Abernethy AP. Decision making and quality of life in the treatment of cancer: a review. Support Care Cancer. 2009;17(2):117–27.

32. Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011;29(7):934–43.

33. Ter-Minassian M, Zhang S, Brooks NV, et al. Association between tumor progression endpoints and overall survival in patients with advanced neuroendocrine tumors. Oncologist. 2017;22(2):165–72.

34. Eichler HG, Bloechl-Daum B, Brasseur D, et al. The risks of risk aversion in drug regulation. Nat Rev Drug Discov. 2013;12(12):907–16.

35. Morel T, Ayme S, Cassiman D, Simoens S, Morgan M, Vande broek M. Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers. Orphanet J Rare Dis. 2016;11(1):70.

36. Ashley D, Thomas D, Gore L, et al. Accepting risk in the acceleration of drug development for rare cancers. Lancet Oncol. 2015;16(4):e190–4.

37. Carr AJ, Higginson IJ. Are quality of life measures patient centred? BMJ. 2001;322(7298):1357–60.

38. Wilm S, Leve V, Santos S. Is it quality of life that patients really want? Assessment from a general practitioner’s perspective. Z Evid Fortbild Qual Gesundhwes. 2014;108(2–3):126–9.

39. Dolan JG, Qian F, Veazie PJ. How well do commonly used data presentation formats support comparative effectiveness evaluations? Med Decis Making. 2012;32(6):840–50.

40. Rothberg MB, Scherer L, Kashef MA, et al. The effect of information presentation on beliefs about the benefits of elective percutaneous coronary intervention. JAMA Intern Med. 2014;174(10):1623–9.

41. Epstein RM, Street RL Jr. Shared mind: communication, decision making, and autonomy in serious illness. Ann Fam Med. 2011;9(5):454–61.

42. Mol PG, Arnardottir AH, Straus SM, et al. Understanding drug preferences, different perspectives. Br J Clin Pharmacol. 2015;79(6):978–87.

43. Johanson V, Wilson B, Abrahamsson A, et al. Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel® given by either self/partner or a health care professional. Patient Prefer Adherence. 2012;6:703–10.

44. Adelman DT, Burgess A, Davies PR. Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study. Med Devices (Auckl). 2012;5:103–9.

45. Modlin IM, Kidd M, Latch I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128(6):1717–51.

46. O’Connor JM, Marmissolle F, Bestani C, et al. Observational study of patients with gastrointestinal carcinoids to assess patient preference for lanreotide Autogel®(R) given by either self/partner or a health care professional. Patient Prefer Adherence. 2012;6:703–10.

47. Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol. 2013;24(12):3040–4.
48. van der Zwan JM, Trama A, et al. Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project. Eur J Cancer. 2013;49(11):2565–78.

49. Ter-Minassian M, Chan JA, Hooshmand SM, et al. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer. 2013;20(2):187–96.

50. Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012;41(3):461–6.

51. Swinburn P, Wang J, Chandiwana D, Mansoor W, Lloyd A. Elicitation of health state utilities in neuroendocrine tumours. J Med Econ. 2012;15(4):681–7.

52. Ayyagari R, Neary M, Li S, Zhao C, Higuchi K, Xie J, Benson AB. Economic evaluation of octreotide LAR versus lanreotide depot in the treatment of metastatic gastrointestinal neuroendocrine tumors (GI-NETs). Poster presented at the 2015 NANETS Symposium; 2015 Oct 15–17. Austin; 2015.

53. Ortendahl JD, Pulgar SJ, Cox D, Bentley TGK, Phan AT. Budget impact of somatostatin analogs (SSAs) as treatment for metastatic gastroenteropancreatic neuroendocrine tumors (mGEP-NETs) in US hospitals. Poster presented at the 13th Annual ENETS Conference; 2016 Mar 9–11. Barcelona; 2016.

54. Casciano R, Chulikavit M, Perrin A, Liu Z, Wang X, Garrison LP. Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States. J Med Econ. 2012;15(Suppl 1):55–64.

55. Lomas J, Culyer T, McCutcheon C, McAuley L, Law S. Conceptualizing and combining evidence for health system guidance. 2005. http://www.chsrfa.ca/kte_docs/Conceptualizing%20and%20combining%20evidence.pdf. Accessed Feb 2010.